A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment

被引：19

作者：

Eligar, Vinay S. ^{[1
]}

Bain, Stephen C. ^{[2
]}

机构：

[1] Univ Wales Hosp, Cardiff CF14 4XW, S Glam, Wales

[2] Swansea Univ, Singleton Hosp, Swansea, W Glam, Wales

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2013年 / 7卷

关键词：

sitagliptin; CKD; chronic kidney disease; renal impairment; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; CHRONIC KIDNEY-DISEASE; INITIAL COMBINATION THERAPY; ONGOING METFORMIN THERAPY; TYPE-2; DIABETIC-PATIENTS; BETA-CELL FUNCTION; GLYCEMIC CONTROL; DOUBLE-BLIND; DPP-4; INHIBITOR; IV INHIBITOR;

D O I：

10.2147/DDDT.S32331

中图分类号：

R914 [药物化学];

学科分类号：

100705 [微生物与生化药学];

摘要：

Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing management or as monotherapy where it is deemed necessary. It has been found to be beneficial in improving beta-cell function and glycemic control, and also is used in special circumstances like chronic kidney disease, with appropriate dose reductions. Overall, cardiovascular outcomes are no different from other oral hypoglycemic agents. In this review article we have summarized all the previous studies relevant to sitagliptin use in clinical practice and emphasized its use in various stages of chronic kidney disease.

引用

页码：893 / 903

页数：11

共 61 条

[1]

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes [J].